Photo od Ahmed Kotb
from daiichisankyo.us
Jun 22, 2025, 11:29
Ahmed Kotb: Choosing the Right DOAC For Your Patient?
Ahmed Kotb, Head of Global Oncology Medical Affairs at Daiichi Sankyo, shared on X:
“Choosing the right DOAC for your patient?
anticoagulant choice based on clinical profiles”
Elderly/Frail- Apixaban, Edoxaban
Obese -Apixaban or Rivaroxaban
CKD Apixaban, Edoxaban 30mg
GI Bleed Risk-Apixaban
Compliance issues- Edoxaban, Rivaroxaban
You can explore more detailed, evidence-based insights on individualized anticoagulant therapy at Hemostasis Today, your source for expert-guided approaches in thrombosis and hemostasis.
-
Sep 23, 2026, 00:08Janar Sathananthan: The Importance of Durable Drug Delivery in DCB Therapy
-
Sep 23, 2026, 00:07Arun V J: How Does a Good Conference Destroy My Ego?
-
Sep 23, 2026, 00:06Akshat Jain: Sickle Cell Disease Is Not One Size Fits All
-
Sep 23, 2026, 00:05Sherri Ozawa: Nicole De Vita’s Iron Deficiency Infographic Recognized at SABM
-
Sep 23, 2026, 00:04Zafar Ali: How Does Hemoglobin Know When to Hold Oxygen and When to Let It Go?
-
Sep 23, 2026, 00:02Ahmed Elsharkawy: Drug-Drug and Drug-Diluent Incompatibilities in ICUs and Hematology Units
-
Sep 22, 2026, 23:58Nishant Rajendra Tiwari: Hereditary TTP With the Same ADAMTS13 Variants but Strikingly Different Disease Courses
-
Sep 22, 2026, 23:57Akhil Santhosh: Pacritinib Versus Ruxolitinib in Myelofibrosis With Thrombocytopenia
-
Sep 22, 2026, 23:56Nathan Punwani: EASIX and sC5b-9 Predict TMA After Allogeneic Stem Cell Transplantation